Vertex’s 22% Sales Growth And Pipeline Gives Biotech Something To Smile About
Sickle Cell Therapy Could Be Next Blockbuster
Executive Summary
In a gloomy start to the year for the biotech sector, Vertex’s strong showing in cystic fibrosis and promising pipeline could lift the mood.
You may also be interested in...
Vertex Diabetes Cell Therapy Back On Track After FDA ‘Hiccup’
The US firm has received the FDA thumbs-up to continue a trial for its novel cell therapy candidate, VX-880, after what was perceived in some circles as an over-cautious decision by the regulator to pause the study in March.
AbbVie Focuses On Humira’s Formulary Positioning Ahead Of US Biosimilars
A year out from US competition to top-seller Humira, AbbVie is negotiating for formulary position alongside biosimilars. Analysts said success there could delay some patent cliff pain for the originator until 2024.
AbbVie Focuses On Humira’s Formulary Positioning Ahead Of Biosimilars
A year out from the US patent expiration for top-seller Humira, AbbVie is negotiating for formulary position alongside biosimilars. Analysts said success there could delay some patent cliff pain until 2024.